This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Allergan, Inc., Other. Active years: 2003-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Brentwood, CA (US) (2003 - 2008)
- Newport Beach, CA (US) (2011 - 2014)
- Harker Heights, TX (US) (2016 - 2019)
Company Filing History:
5 out of 2,287 
2 out of 834,601 Years Active: 2003-2019
Title: The Innovative Contributions of Kelly M Harrison
Introduction
Kelly M Harrison is a prominent inventor based in Harker Heights, TX (US). She has made significant contributions to the field of ocular therapy, holding a total of 7 patents. Her work focuses on developing therapeutic materials that enhance treatment options for eye conditions.
Latest Patents
One of her latest patents is titled "Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues." This invention involves ophthalmically therapeutic materials, including liquid-containing compositions and polymeric drug delivery systems. The therapeutic component consists of a glucocorticoid derivative that, when delivered to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment. The patent also describes methods for making and using these innovative materials.
Career Highlights
Throughout her career, Kelly has worked with notable companies, including Allergan, Inc. Her experience in the pharmaceutical industry has allowed her to develop groundbreaking solutions for ocular therapies.
Collaborations
Kelly has collaborated with esteemed colleagues, including Jeffrey L Edelman and David W Schneider. These partnerships have contributed to her success and the advancement of her inventions.
Conclusion
Kelly M Harrison's innovative work in ocular therapy demonstrates her commitment to improving eye health through her patented inventions. Her contributions continue to influence the field and provide new treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile